112 related articles for article (PubMed ID: 28738534)
1. High expression of CD47 predicts adverse prognosis in Chinese patients and suppresses immune response in melanoma.
Fu W; Li J; Zhang W; Li P
Biomed Pharmacother; 2017 Sep; 93():1190-1196. PubMed ID: 28738534
[TBL] [Abstract][Full Text] [Related]
2. Exosomal CD47 Plays an Essential Role in Immune Evasion in Ovarian Cancer.
Shimizu A; Sawada K; Kobayashi M; Yamamoto M; Yagi T; Kinose Y; Kodama M; Hashimoto K; Kimura T
Mol Cancer Res; 2021 Sep; 19(9):1583-1595. PubMed ID: 34016744
[TBL] [Abstract][Full Text] [Related]
3. Antibody Therapy Targeting CD47 and CD271 Effectively Suppresses Melanoma Metastasis in Patient-Derived Xenografts.
Ngo M; Han A; Lakatos A; Sahoo D; Hachey SJ; Weiskopf K; Beck AH; Weissman IL; Boiko AD
Cell Rep; 2016 Aug; 16(6):1701-1716. PubMed ID: 27477289
[TBL] [Abstract][Full Text] [Related]
4. CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.
Liu R; Wei H; Gao P; Yu H; Wang K; Fu Z; Ju B; Zhao M; Dong S; Li Z; He Y; Huang Y; Yao Z
Oncotarget; 2017 Jun; 8(24):39021-39032. PubMed ID: 28380460
[TBL] [Abstract][Full Text] [Related]
5. CD47 expression and CD163
Imam R; Chang Q; Black M; Yu C; Cao W
BMC Cancer; 2021 Mar; 21(1):320. PubMed ID: 33765961
[TBL] [Abstract][Full Text] [Related]
6. Expression and Prognostic Significance of CD47-SIRPA Macrophage Checkpoint Molecules in Colorectal Cancer.
Sugimura-Nagata A; Koshino A; Inoue S; Matsuo-Nagano A; Komura M; Riku M; Ito H; Inoko A; Murakami H; Ebi M; Ogasawara N; Tsuzuki T; Takahashi S; Kasugai K; Kasai K; Inaguma S
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33799989
[TBL] [Abstract][Full Text] [Related]
7. Intravenous delivery of siRNA targeting CD47 effectively inhibits melanoma tumor growth and lung metastasis.
Wang Y; Xu Z; Guo S; Zhang L; Sharma A; Robertson GP; Huang L
Mol Ther; 2013 Oct; 21(10):1919-29. PubMed ID: 23774794
[TBL] [Abstract][Full Text] [Related]
8. CD47 is an adverse prognostic factor and a therapeutic target in gastric cancer.
Yoshida K; Tsujimoto H; Matsumura K; Kinoshita M; Takahata R; Matsumoto Y; Hiraki S; Ono S; Seki S; Yamamoto J; Hase K
Cancer Med; 2015 Sep; 4(9):1322-33. PubMed ID: 26077800
[TBL] [Abstract][Full Text] [Related]
9. CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration.
Shi M; Gu Y; Jin K; Fang H; Chen Y; Cao Y; Liu X; Lv K; He X; Lin C; Liu H; Li H; He H; Qin J; Li R; Zhang H; Zhang W
Cancer Immunol Immunother; 2021 Jul; 70(7):1831-1840. PubMed ID: 33389016
[TBL] [Abstract][Full Text] [Related]
10. Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade.
Anderson KL; Snyder KM; Ito D; Lins DC; Mills LJ; Weiskopf K; Ring NG; Ring AM; Shimizu Y; Mescher MF; Weissman IL; Modiano JF
Melanoma Res; 2020 Apr; 30(2):147-158. PubMed ID: 31205227
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathological and Prognostic Significance of CD47 Expression in Lung Neuroendocrine Tumors.
Orozco-Morales M; Avilés-Salas A; Hernández-Pedro N; Catalán R; Cruz-Rico G; Colín-González AL; Dosal-Mancilla E; Barrios-Bernal P; Arrieta O
J Immunol Res; 2021; 2021():6632249. PubMed ID: 34195295
[TBL] [Abstract][Full Text] [Related]
12. A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments.
Benesova I; Capkova L; Ozaniak A; Pacas P; Kopeckova K; Galova D; Lischke R; Buchler T; Ozaniak Strizova Z
J Cancer Res Clin Oncol; 2024 Mar; 150(3):134. PubMed ID: 38493445
[TBL] [Abstract][Full Text] [Related]
13. CD47 promotes cell growth and motility in epithelial ovarian cancer.
Wang CL; Lin MJ; Hsu CY; Lin HY; Tsai HP; Long CY; Tsai EM; Hsieh TH; Wu CH
Biomed Pharmacother; 2019 Nov; 119():109105. PubMed ID: 31493748
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathologic and Prognostic Significance of CD47 Expression and Tumor-associated Macrophages in Endometrial Carcinoma.
Sercan Ç; Haberal Reyhan AN; Özen Ö; Ayhan A
Int J Gynecol Pathol; 2022 Jul; 41(4):397-406. PubMed ID: 34282107
[TBL] [Abstract][Full Text] [Related]
15. CD47 is not Over-Expressed in Fibrolamellar Hepatocellular Carcinoma.
Cooney T; Wei MC; Rangaswami A; Xu L; Sage J; Hazard FK
Ann Clin Lab Sci; 2017 Aug; 47(4):395-402. PubMed ID: 28801364
[TBL] [Abstract][Full Text] [Related]
16. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
17. Selective Blockade of the Ubiquitous Checkpoint Receptor CD47 Is Enabled by Dual-Targeting Bispecific Antibodies.
Dheilly E; Moine V; Broyer L; Salgado-Pires S; Johnson Z; Papaioannou A; Cons L; Calloud S; Majocchi S; Nelson R; Rousseau F; Ferlin W; Kosco-Vilbois M; Fischer N; Masternak K
Mol Ther; 2017 Feb; 25(2):523-533. PubMed ID: 28153099
[TBL] [Abstract][Full Text] [Related]
18. CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models.
Xu JF; Pan XH; Zhang SJ; Zhao C; Qiu BS; Gu HF; Hong JF; Cao L; Chen Y; Xia B; Bi Q; Wang YP
Oncotarget; 2015 Sep; 6(27):23662-70. PubMed ID: 26093091
[TBL] [Abstract][Full Text] [Related]
19. Concurrent Expression of CD47 and CD44 in Colorectal Cancer Promotes Malignancy.
Fujiwara-Tani R; Sasaki T; Ohmori H; Luo Y; Goto K; Nishiguchi Y; Mori S; Nakashima C; Mori T; Miyagawa Y; Kawahara I; Fujii K; Kishi S; Tatsumoto N; Kuniyasu H
Pathobiology; 2019; 86(4):182-189. PubMed ID: 31132784
[TBL] [Abstract][Full Text] [Related]
20. Targeting the Cancer Biomarker CD47: A Review on the Diverse Mechanisms of the CD47 Pathway in Cancer Treatment.
Zhang L; Huang H
Anticancer Agents Med Chem; 2016; 16(6):658-67. PubMed ID: 26446381
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
